Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT7 | O95251 | 20/20 | 0.79 |
| ▸ | KAT6A | Q92794 | 20/20 | 0.79 |
| ▸ | KAT6B | Q8WYB5 | 13/20 | 0.79 |
| ▸ | KAT5 | Q92993 | 13/20 | 0.79 |
| ▸ | KAT8 | Q9H7Z6 | 13/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22823930 | 0.93 | KAT7 (0.78) | KAT7KAT6AKAT6BKAT5KAT8 | |
| SCHEMBL22817406 | 0.88 | KAT7 (1.00) | KAT7KAT6AKAT6BKAT5KAT8 | |
| SCHEMBL22802418 | 0.88 | KAT7 (1.00) | KAT7KAT6AKAT6BKAT5KAT8 | |
| SCHEMBL24667503 | 0.88 | KAT7 (0.71) | KAT7KAT6AKAT6BKAT5KAT8 | |
| SCHEMBL22823967 | 0.88 | KAT6A (0.73) | KAT7KAT6AKAT6BKAT5KAT8 | |
| Prifetrastat SCHEMBL22802427 | 0.88 | KAT7 (0.90) | KAT7KAT6AKAT6BKAT5KAT8 | |
| SCHEMBL22828701 | 0.88 | KAT7 (1.00) | KAT7KAT6AKAT6BKAT5KAT8 | |
| SCHEMBL22817389 | 0.88 | KAT7 (1.00) | KAT7KAT6AKAT6BKAT5KAT8 | |
| SCHEMBL22828479 | 0.88 | KAT7 (1.00) | KAT7KAT6AKAT6BKAT5KAT8 | |
| SCHEMBL22823792 | 0.88 | KAT6A (0.70) | KAT7KAT6AKAT6BKAT5KAT8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220251075-A1 | Cycloalkyl and Heterocycloalkyl Benzisoxazole Sulfonamide Derivatives | PFIZER INC. | 2022-08-11 | — | — | US | disclosed |
| WO-2020254989-A1 | CYCLOALKYL AND HETEROCYCLOALKYL BENZISOXAZOLE SULFONAMIDE DERIVATIVES | PFIZER INC. (US) | 2020-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220251075-A1 | Cycloalkyl and Heterocycloalkyl Benzisoxazole Sulfonamide Derivatives | BRIX1, CCNA1, RB1 | KAT7 1804/4885KAT6A 3964/4885KAT6B 2525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.